Navigation Links
The Outlook for Pharmaceuticals in South East Asia

NEW YORK, Dec. 13, 2012 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

The Outlook for Pharmaceuticals in South East Asia

The eight pharmaceutical markets of South East Asia are developing at markedly different speeds and are characterised by both contrasting and similar macroenvironments. These markets are projected to have a total pharmaceutical market value of US$69.1 billion at retail prices in 2016.

Established…South Korea is the largest market in this region and the fourth largest in the Asia Pacific region. Other advanced markets such as Taiwan and Singapore are both relatively small, with growth limited by the size of these island nations. These three countries have a high percentage of population over 65, a growing incidence of lifestyle diseases and large health expenditures, which present many opportunities for pharmaceutical companies. However, their governments are increasingly employing protectionist measures that deter foreign companies. The biologic sectors in these markets are witnessing rapid growth due to advanced technology capabilities, extensive R&D operations and strong government support.


Indonesia, Thailand and the Philippines are fairly large emergent pharmaceutical markets, with large populations and steadily growing economies. Despite concerns over counterfeiting and low efficacy of generic products, IPR protection and manufacturing standards are improving thanks to effective national regulations, foreign investment and joint-ventures with multinational companies. Malaysia and Vietnam are small pharmaceutical markets, typified by rapid economic growth, increasing foreign investment and support from national government. These five markets have significant OTC sectors and rapidly expanding generic sectors, and present previously untapped populations for potential foreign pharmaceutical companies.

Complete quarterly-updated analysis to keep you informedNow you can easily evaluate these markets with The Outlook for Pharmaceuticals in South East Asia. Each report provides individual and highly-detailed analysis of the market, looking at the key regulatory, political, economic and corporate developments in the wider context of market structure, service and access. The reports are available individually, or as a discounted collection, and prices include eight completely updated reports sent quarterly, together with a comprehensive statistical appendix. There are over 60 markets covered in the worldwide series. Focus on Biotechnolog - A research-friendly environment...These markets are keen to attract high value investment and have identified biotechnology and biopharmaceutical research as key areas. Their governments strongly advocate the growth of biotechnology.


The government has indentified biotechnology as one the core technologies to accelerate the transformation of the country into a knowledge-based economy by the year 2020. As a result of this initiative, a number of new biopharmaceutical research companies have emerged.

SingaporeThe biologic sector is growing, with several large multinational companies investing a total of US$2.0 billion to set up biologic facilities. The government is increasing its investment in biomedical sciences research over the period 2011 to 2015.

South Korea

The biologic sector is witnessing rapid growth and many domestic companies have expanded their operations in 2011. Several significant competitive strategies have been completed in 2011.

TaiwanThe government has been investing heavily in biotechnology research capability and this has helped facilitate the growth of the biologic sector. The plan is to double the annual output of the sector over the period 2009 to 2013. INDONESIADue to the sheer size of the population, Indonesia cannot simply be dismissed. The Indonesian pharmaceutical market is projected to grow at a high single-digit CAGR in US dollar terms during the forecast period, and it will be the sixth largest pharmaceutical market in the Asia Pacific region by 2016. However, despite the country possessing huge manufacturing capabilities, the complete lack of R&D in domestic companies could affect the market, especially if IPR regulations were tightened. Although multinationals will be unhappy at the legislation requiring all drugs in the Indonesian market to have been manufactured in Indonesia, it could potentially reduce costs in the long term for both the manufacturer and the consumer.


The Philippines has some of the highest drug prices in the world. Changes brought about by the controversial Cheaper Medicine Act have impacted the Philippines pharmaceutical market in a number of areas, including IP laws, competition and drug price control mechanisms. Since the Act's implementation, a considerable number of drugs have seen price reductions by up to a half. The immediate term will be the most volatile, as the government battles with the international pharmaceutical industry for ground in the market, which up until recently experienced a free-market policy with no price regulations in place.

SOUTH KOREAThe implementation of the EU-Korea Free Trade Agreement (FTA) will provide EU companies with better access to the South Korean pharmaceutical market by paving the way for elimination of tariffs on EU pharmaceutical exports to the country. The volume and value of EU pharmaceutical exports are expected to increase with the implementation of EU-Korea FTA, posing a potential threat to US pharmaceutical exporters. The EU-Korea FTA also stipulates that South Korean authorities will be required to align their practices with international standards through an improved regulatory environment. In particular, the EU-Korea FTA will aim to ensure the strengthening of transparency in drug pricing decisions.


The Drug Administration of Vietnam (DAV) has warned that drug prices could rise slightly in 2011 due to volatile raw material prices and the VND-US$ exchange rate. The Vietnam Pharmaceutical Companies Association (VNPCA) has forecasted higher sales prices for both imported and Vietnamese drugs in 2011, due to higher input costs and rising world prices. To review the local pharmaceutical market and prevent large drug price increases, the DAV has announced several measures that include; stepping-up the inspection of drug price quotations by pharmaceutical companies, supervising the enforcement of state regulations on drug price management and exercising sanctions on violators.

To order this report:Drug_and_Medication Industry: The Outlook for Pharmaceuticals in South East Asia

Nicolas Bombourg



US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
2. Advance Recruitment Delighted With Positive Outlook for Medical Device Sales Industry
3. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
4. The CMO Market Outlook to 2017
5. Middle East and Africa Endoscopy Devices Market Outlook to 2017 - Flexible Endoscopes, Rigid Endoscopes, Endoscopy Visualization Systems, Capsule Endoscope Systems and Others
6. United States ENT Devices Market Outlook to 2018 - Diagnostic Devices, Hearing Aid Devices, Hearing Implants and Others
7. United Kingdom ENT Devices Market Outlook to 2018 - Diagnostic Devices, Hearing Aid Devices, Hearing Implants and Others
8. India Surgical Equipment Market Outlook to 2018- Electrosurgical Devices, Hand Instruments and Surgical Sutures
9. United States Surgical Equipment Market Outlook to 2018- Electrosurgical Devices, Hand Instruments and Surgical Sutures
10. China ENT Devices Market Outlook to 2018 - Diagnostic Devices, Hearing Aid Devices, Hearing Implants and Others
11. India ENT Devices Market Outlook to 2018 - Diagnostic Devices, Hearing Aid Devices, Hearing Implants and Others
Post Your Comments:
(Date:12/1/2015)... -- CytRx Corporation (NASDAQ: CYTR ), a biopharmaceutical ... that it has reached its enrollment target of 400 ... trial of aldoxorubicin in patients with previously treated soft ... in Q1 2016. The Phase 3 trial is a randomized, ... from the FDA at 79 sites in ...
(Date:12/1/2015)... 1, 2015   Craneware, Inc ., the ... today announced the company will showcase a new ... ® solution at the American Society for ... . The new features are focused on simplifying ... and managing enterprise-wide pharmacy charges to ensure compliance ...
(Date:12/1/2015)... Germany , December 1, 2015 /PRNewswire/ ... leading global manufacturer of eye and gaze tracking solutions, ... SMI remote eye trackers as a component of its ... concussions, eye sight, and medical and performance issues in ... part of SMI,s mass-market-ready eye tracking platform, which is ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... World Patent Marketing ... Jar, a container patent that allows for easier packing and organizing of items into ... worth $90 billion," says Scott Cooper, CEO and Creative Director of World Patent Marketing ...
(Date:12/1/2015)... ... ... Tampa is the first health care provider in the region to offer the vBloc® ... a vagal blocking therapy, delivered via the Maestro® System, for the treatment of adult patients ... 40 to 45 kg, or a BMI of at least 35 to 39.9 kg with ...
(Date:12/1/2015)... ... ... Dr. Paul Vitenas, one of the top cosmetic surgeons in Texas ... the Best Single Physician Practice in the nation. Dr. Vitenas and his practice were ... the industry publication. , Dr. Vitenas said he was very honored to receive ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... the 7th Annual 2015 Golden Bridge Business Awards under the New Products and ... zero capex web based sample management software that helps labs organize ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... facilities, radiographic technicians must mark the film for accurate interpretation by the radiologist. ... of. Fortunately, an inventor from Sacramento, Calif., has found a way to alleviate ...
Breaking Medicine News(10 mins):